Date: 2013-08-29
Type of information: Series A financing round
Company: ObsEva (Switzerland)
Investors: Sofinnova Partners (France) Sofinnova Ventures (USA) Novo A/S (Denamrk)
Amount: CHF 32 million (€25.6 million)
Funding type: series A financing round
Planned used: Concurrently to the financing, ObsEva has signed a worldwide licensing agreement with Merck Serono to develop and commercialize certain of their compounds in the field of obstetrics. Merck Serono has also taken a minority equity stake in the company. The Series A funding will enable ObsEva’s management team to accelerate the development of these compounds which have the potential to be best-in-class products.
Others: Sofinnova Partners, an independent venture capital firm based in Paris, France led the Series A financing round that allowed ObsEva SA, a Swiss biopharmaceutical company specialized in women’s reproductive medicine, to raise CHF 32 million ( €25.6 million). Sofinnova Ventures and Novo A/S joined as co-investors. ObsEva focuses primarily on therapies for the treatment of preterm labor. The firm was co-founded in November 2012 by Ernest Loumaye, MD, PhD, a serial entrepreneur Sofinnova Partners successfully backed a few years ago with PregLem SA., a women’s health venture that focused on the treatment of uterine fibroids. PregLem was acquired by Gedeon Richter for CHF 445 million (€361 million) in 2010. ObsEva’s management team is spearheaded by its two co-founders, Ernest Loumaye, MD, PhD, Chief Executive Officer, and André Chollet, PhD, Chief Scientific Officer.
Therapeutic area: Gynecology - Women's health
